 NEW YORK, March 23, 2021 PRNewswire -- Oramed Pharmaceuticals Inc. Nasdaq: ORMP TASE: ORMP a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes T2D. The studies are taking place under U.S. Food and Drug Administration FDA approved protocols to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months. 